New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2−Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III

New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2−Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III

Early breast cancer (EBC) treatment has evolved from radical surgery to a multidisciplinary approach, integrating radiotherapy, chemotherapy, targeted therapy, and hormone therapy with surgery to ensure the best possible outcome. Despite these advancements, hormone receptor-positive (HR+)/Human Epid...

Full description

Saved in:
Bibliographic Details
Main Authors: Nicola Battelli, Carmela Mocerino, Michele Montedoro, Mirco Pistelli, Ilaria Portarena, Mario Rosanova, Tina Sidoni, Patrizia Vici
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Current Oncology
Subjects:
breast cancer
adjuvant therapy
ribociclib
stage II
stage III
adherence
Online Access:https://www.mdpi.com/1718-7729/32/4/192
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items